Zydus, Torrent Pharma Partner to Co-Market Semaglutide Injection in India

Zydus Lifesciences Ltd has entered into a licensing and supply agreement with Torrent Pharmaceuticals Ltd to co-market semaglutide injection in India, the company said in a press release.

Under the agreement, Zydus will manufacture and supply the product, while Torrent Pharma will have semi-exclusive rights to market it in India under the brand name Sembolic. Zydus will market the drug under its own brands Semaglyn, Mashema and Alterme, the release said.

As part of the deal, Torrent Pharma will pay Zydus an upfront licensing fee.

The companies said the semaglutide injection has been developed in a prefilled cartridge format and is administered using a reusable pen device designed to improve patient convenience and treatment adherence.

The therapy is used for treating adults with type 2 diabetes where blood sugar levels are not adequately controlled. It can be used as a standalone treatment where metformin is not suitable or alongside other diabetes medications. It is also indicated for chronic weight management in adults with obesity or those who are overweight with related health conditions such as hypertension, type 2 diabetes, or dyslipidaemia.

The companies said the partnership combines Zydus’ product development and manufacturing capabilities with Torrent Pharma’s strong domestic market presence to expand access to advanced GLP-1 therapies in India.